Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study.
Squifflet
Jean-Paul
JP
Cliniques Universitaires Saint-Luc, University of Louvain Medical School, Saint Luc Hospital, 10 Hippocrates Avenue, B-1200 Brussels, Belgium. Jean-Paul.Squifflet@chir.ucl.ac.be
Vanrenterghem
Y
Y
van Hooff
J P
JP
Salmela
K
K
Rigotti
P
P
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005060:Europe; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012086:Reoperation; D016559:Tacrolimus / Q000627:therapeutic use; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D008077:Lipoproteins, LDL; D002784:Cholesterol; D009173:Mycophenolic Acid; D016559:Tacrolimus